最后一例埃博拉确诊患者Masika已从治疗中心出院，标志着刚果民主共和国的疫情防控工作取得重大进展1。自2018年8月疫情宣布以来，疫情曾在高峰期每周报告超过120例确诊病例，影响遍布28个卫生区且相隔1200公里的地区1。为应对这场危机，当局建立了11个实验室和11个埃博拉治疗中心，完成约160万次边境筛查，并为30万人进行了疫苗接种，同时对约25万人进行了追踪，为1169名幸存者提供了护理1。
然而，世界卫生组织警告疫情尚未正式宣布结束1。按照规程，在最后一例患者检测阴性后需要等待42天（两个潜伏期）才能宣布疫情终止1。与此同时，防控工作面临严峻挑战：自疫情宣布以来，卫生设施遭受420次攻击，导致11名卫生工作者和患者死亡、86人受伤1。更为紧迫的是，WHO面临立即2000万美元的资金缺口1。若资金短缺无法补充，可能导致防控能力下降，甚至引发病例反弹——西非埃博拉疫情结束后曾出现过类似情况1。
The Ebola outbreak in the Democratic Republic of the Congo has reached a critical juncture with the discharge of the final confirmed patient, Masika, from a treatment center, signaling the epidemic's approach to conclusion 1. Since the outbreak was declared in August 2018, the response has involved vaccination of over 300,000 people, establishment of 11 laboratories and 11 Ebola treatment centers, and completion of approximately 1.6 million border screenings 1. Approximately 250,000 people have been tracked and 1,169 survivors have received ongoing care 1. At the outbreak's peak, over 120 cases were reported weekly across 28 health zones spanning 1,200 kilometers 1.
However, the World Health Organization has cautioned that the epidemic has not formally ended and remains under heightened surveillance 1. Following WHO protocols, a 42-day monitoring period—equivalent to two incubation periods—must elapse after the final patient tests negative before the outbreak can be officially declared concluded 1. This extended observation window reflects concerns about potential resurgence; similar flare-ups occurred following the end of the West African Ebola epidemic 1.
A significant challenge threatens containment efforts: the response faces an immediate funding gap of $20 million 1. Without adequate resources, operational capacity for prevention and control could deteriorate, potentially allowing the virus to resurge 1. Additionally, the response has endured considerable obstacles, including 420 attacks on health facilities since August 2018 that resulted in 11 deaths among health workers and patients and injured 86 others 1.
评论
还没有评论，欢迎留下第一条。